Fritextsökning
Innehållstyper
-
New Insights into Microscopy
Watch the recording of our free webinar.
-
Neogap värvar tungt namn inom cellterapi
Bioteknikbolaget Neogap Therapeutics fyller på styrelsen med expertis inom cellterapi i form av professor Jonas Mattsson.
-
Allogene discontinues investigational antibody following patient death
U.S. biotechnology company Allogene Therapeutics is fully discontinuing the use of its experimental antibody ALLO-647 following the death of a patient in its pi...
-
Explore the latest trends and innovations in quality assurance and manufacturing
ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.
-
Automate E2E Image Analysis Pipelines
ZEISS arivis Pro - Your End-to-End Scientific Image Analysis Software.
-
Explore the possibilities of the new ZEISS METROTOM 800 320 kV
Free ZEISS webinar July 10, 9:00-9:45 AM and 5:00-5:45 PM.
-
Anna Törner: ”Varför inte slå till på en ADHD-diagnos till kampanjpris?”
”Det är självklart positivt att neuropsykiatriska diagnoser inte upplevs som stigmatiserande, men just när det gäller ADHD kan jag inte låta bli att undra om de...
-
Recipharms AI-satsning får stöd från Gates-stiftelse
Svenska Recipharm får utökad finansiering från Bill & Melinda Gates Foundation för att utveckla AI-drivna tillverkningsteknologier. Syftet är att sänka produkti...
-
Government apoints new experts to medicine and health council
Johanna Fälting, Head of Research at BioArctic, and physician Markus Lingman have been appointed as new members of the Swedish Research Council’s Subject Counci...
-
Lund University’s record-breaking recruitment – attracting researchers from around the world
The Swedish university is launching its largest international recruitment effort ever, aiming to hire 25 researchers globally, including several in the medical field.
-
Alvotech flyttar in i svenskt life sciene-kluster
Isländska Alvotech, noterade på Stockholmsbörsen, flyttar in på Campus Solna. ”Alvotech strävar efter att avsevärt expandera sin forsknings- och utvecklingsverk...
-
Agreement in the EU on eight years of data exclusivity for new medicines
New pharmaceuticals will be covered by eight years of data exclusivity, according to the proposed new pharmaceutical legislation that EU countries have now agre...
-
Cleveland Clinic: Kirurgi gav fler långsiktiga fördelar än GLP-1-läkemedel
Metabol kirurgi minskade riskerna för död, hjärtsjukdom, njursvikt och ögonskador mer än GLP-1-läkemedel under en tioårsperiod. Det enligt en ny studie från Cle...
-
Join our measuringhero Jay on the innovation tour
Experience our latest innovation from the Control fair.
-
Recipharm i samarbete om ny ALS-behandling
Recipharm ska samarbeta med israeliska Neurosense Therapeutics om att ta en ny behandling för den neurodegenerativa sjukdomen ALS vidare till fas III-studier.
-
Smartzoom 100 – The New Digital Microscope for Maximum Efficiency
Free webinar July 1, 9:00-9:45 AM CEST and 5:00-5:45 PM CEST.
-
CTC Clinical Trial Consultants AB
-
Charged with illegal pharmaceutical sales – alleged earnings of 23 million
For at least five years, two men allegedly carried out illegal sales of pharmaceuticals and supplements, amassing millions. They are now facing charges at Söder...
-
Novo Nordisk cuts ties with Hims & Hers after Wegovy dispute
Novo Nordisk is ending its collaboration with Hims & Hers Health due to concerns about the company’s sales and marketing practices related to the weight-loss drug Wegovy.
-
Large study: The benefits and risks of obesity medications
Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the risk of others. This is according t...
-
Lundbeck presenterar första behandlingen mot MSA
Danska läkemedelsbolaget Lundbeck har utvecklat antikroppen amlenetug, som kan innebära den första behandling av multipel systematrofi (MSA).
-
The New Precise Magazine is Available Now
Download the new issue.
-
Compact and leak-tight powerhouse
Media-separated solenoid valve VYKA from Festo is virtually leak-free
-
Improved processes and more
Discover the full potential and benefits.